SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1757 4676 OR L773:1757 4684 "

Sökning: L773:1757 4676 OR L773:1757 4684

  • Resultat 1-10 av 84
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Ajore, Ram, et al. (författare)
  • Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
  • 2017
  • Ingår i: EMBO Molecular Medicine. - : EMBO. - 1757-4684 .- 1757-4676. ; 9:4, s. 498-507
  • Tidskriftsartikel (refereegranskat)abstract
    • Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large-scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53-dependent negative selection, such lesions are underrepresented in TP53-intact tumors (P ≪ 10−10), and shRNA-mediated knockdown of RPGs activated p53 in TP53-wild-type cells. In contrast, we did not see negative selection of RPG deletions in TP53-mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.
  •  
3.
  •  
4.
  • Appelberg, S., et al. (författare)
  • A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
  • 2022
  • Ingår i: EMBO Molecular Medicine. - : EMBO. - 1757-4676 .- 1757-4684. ; 14:10
  • Tidskriftsartikel (refereegranskat)abstract
    • New variants in the SARS-CoV-2 pandemic are more contagious (Alpha/Delta), evade neutralizing antibodies (Beta), or both (Omicron). This poses a challenge in vaccine development according to WHO. We designed a more universal SARS-CoV-2 DNA vaccine containing receptor-binding domain loops from the huCoV-19/WH01, the Alpha, and the Beta variants, combined with the membrane and nucleoproteins. The vaccine induced spike antibodies crossreactive between huCoV-19/WH01, Beta, and Delta spike proteins that neutralized huCoV-19/WH01, Beta, Delta, and Omicron virus in vitro. The vaccine primed nucleoprotein-specific T cells, unlike spike-specific T cells, recognized Bat-CoV sequences. The vaccine protected mice carrying the human ACE2 receptor against lethal infection with the SARS-CoV-2 Beta variant. Interestingly, priming of cross-reactive nucleoprotein-specific T cells alone was 60% protective, verifying observations from humans that T cells protect against lethal disease. This SARS-CoV vaccine induces a uniquely broad and functional immunity that adds to currently used vaccines. 
  •  
5.
  •  
6.
  • Ayoglu, Burcu, et al. (författare)
  • Affinity proteomics within rare diseases : a BIO-NMD study for blood biomarkers of muscular dystrophies
  • 2014
  • Ingår i: EMBO Molecular Medicine. - : EMBO. - 1757-4676 .- 1757-4684. ; 6:7, s. 918-936
  • Tidskriftsartikel (refereegranskat)abstract
    • Despite the recent progress in the broad-scaled analysis of proteins in body fluids, there is still a lack in protein profiling approaches for biomarkers of rare diseases. Scarcity of samples is the main obstacle hindering attempts to apply discovery driven protein profiling in rare diseases. We addressed this challenge by combining samples collected within the BIO-NMD consortium from four geographically dispersed clinical sites to identify protein markers associated with muscular dystrophy using an antibody bead array platform with 384 antibodies. Based on concordance in statistical significance and confirmatory results obtained from analysis of both serum and plasma, we identified eleven proteins associated with muscular dystrophy, among which four proteins were elevated in blood from muscular dystrophy patients: carbonic anhydrase III (CA3) and myosin light chain 3 (MYL3), both specifically expressed in slow-twitch muscle fibers and mitochondrial malate dehydrogenase 2 (MDH2) and electron transfer flavo-protein A (ETFA). Using age-matched sub-cohorts, 9 protein profiles correlating with disease progression and severity were identified, which hold promise for the development of new clinical tools for management of dystrophinopathies.
  •  
7.
  • Bahnan, Wael, et al. (författare)
  • A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function
  • 2023
  • Ingår i: EMBO Molecular Medicine. - : EMBO. - 1757-4684 .- 1757-4676. ; 15:2, s. 1-21
  • Tidskriftsartikel (refereegranskat)abstract
    • Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments. Here, we have generated antibodies derived from the memory B cells of an individual who had successfully cleared a group A streptococcal infection. The antibodies bind with high affinity in the central region of the surface-bound M protein. Such antibodies are typically non-opsonic. However, one antibody could effectively promote vital immune functions, including phagocytosis and in vivo protection. Remarkably, this antibody primarily interacts through a bivalent dual-Fab cis mode, where the Fabs bind to two distinct epitopes in the M protein. The dual-Fab cis-binding phenomenon is conserved across different groups of M types. In contrast, other antibodies binding with normal single-Fab mode to the same region cannot bypass the M protein's virulent effects. A broadly binding, protective monoclonal antibody could be a candidate for anti-streptococcal therapy. Our findings highlight the concept of dual-Fab cis binding as a means to access conserved, and normally non-opsonic regions, regions for protective antibody targeting.
  •  
8.
  •  
9.
  • Betsholtz, Christer (författare)
  • Cell-cell signaling in blood vessel development and function
  • 2018
  • Ingår i: EMBO Molecular Medicine. - : EMBO. - 1757-4676 .- 1757-4684. ; 10:3
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • The blood vasculature is an organ pervading all other organs (almost). During vascular development, cell-cell signaling by extracellular ligands and cell surface receptors ensure that new vessels sprout into non-vascularized regions and simultaneously acquire organ-specific specializations and adaptations that match the local physiological needs. The vessels thereby specialize in their permeability, molecular transport between blood and tissue, and ability to regulate blood flow on demand. Over the past decades, we have learnt about the generic cell-cell signaling mechanisms governing angiogenic sprouting, mural cell recruitment, and vascular remodeling, and we have obtained the first insights into signals that induce and maintain vascular organotypicity. However, intra-organ vascular diversity and arterio-venous hierarchies complicate the molecular characterization of the vasculature's cellular building blocks. Single-cell RNA sequencing provides a way forward, as it allows elucidation at a genome-wide and quantitative level of the transcriptional diversity occurring within the same cell types at different anatomical positions and levels of arterio-venous hierarchy in the organs. In this Louis-Jeantet Prize Winner: Commentary, I give a brief overview of vascular development and how recent advances in the field pave the way for more systematic efforts to explore vascular functions in health and disease.
  •  
10.
  • Biel, D., et al. (författare)
  • sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease
  • 2023
  • Ingår i: Embo Molecular Medicine. - : EMBO. - 1757-4676 .- 1757-4684. ; 15:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Here, we used CSF sTREM2 to investigate disease stage-dependent drivers of microglial activation and to determine downstream consequences on AD progression. We included 402 patients with measures of earliest beta-amyloid (CSF A beta(1-42)) and late-stage fibrillary A beta pathology (amyloid-PET centiloid), as well as sTREM2, p-tau(181), and FDG-PET. To determine disease stage, we stratified participants into early A beta-accumulators (A beta CSF+/PET-; n = 70) or late A beta-accumulators (A beta CSF+/PET+; n = 201) plus 131 controls. In early A beta-accumulators, higher centiloid was associated with cross-sectional/longitudinal sTREM2 and p-tau(181) increases. Further, higher sTREM2 mediated the association between centiloid and cross-sectional/longitudinal p-tau(181) increases and higher sTREM2 was associated with FDG-PET hypermetabolism. In late A beta-accumulators, we found no association between centiloid and sTREM2 but a cross-sectional association between higher sTREM2, higher p-tau(181) and glucose hypometabolism. Our findings suggest that a TREM2-related microglial response follows earliest A beta fibrillization, manifests in inflammatory glucose hypermetabolism and may facilitate subsequent p-tau(181) increases in earliest AD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 84
Typ av publikation
tidskriftsartikel (82)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (78)
övrigt vetenskapligt/konstnärligt (6)
Författare/redaktör
Zetterberg, Henrik, ... (9)
Hansson, Oskar (9)
Blennow, Kaj, 1958 (7)
Janelidze, Shorena (7)
Palmqvist, Sebastian (6)
Mattsson-Carlgren, N ... (5)
visa fler...
Mirazimi, A (4)
Stomrud, Erik (4)
Kroemer, G (3)
Dage, Jeffrey L. (3)
Penninger, JM (3)
Salvadó, Gemma (3)
Suárez-Calvet, Marc (3)
Gispert, Juan Doming ... (3)
Ashton, Nicholas J. (3)
Smith, Ruben (3)
Rydén, Lisa (2)
Aartsma-Rus, A. (2)
Pontén, Fredrik (2)
Uhlén, Mathias (2)
Nilsson, Peter (2)
Holmgren, A (2)
Lauschke, VM (2)
Lendahl, U (2)
Fischler, B (2)
Xie, W (2)
Adori, C (2)
Blennow, Kaj (2)
Borg, Åke (2)
Shekari, Mahnaz (2)
Pettersson, S (2)
Karikari, Thomas (2)
Montoliu-Gaya, Laia (2)
Lantero Rodriguez, J ... (2)
Turunen, S. Pauliina (2)
Lehti, Kaisa (2)
Chen, Yilun (2)
Winter, Christof (2)
Saal, Lao (2)
Fredriksson, L (2)
Ossenkoppele, Rik (2)
Sauvat, A (2)
Kepp, O (2)
Strandberg, Olof (2)
Lehto, T (2)
Bryja, V (2)
Leuzy, Antoine (2)
Zetterberg, Henrik (2)
Hankeova, S (2)
Zitvogel, L (2)
visa färre...
Lärosäte
Karolinska Institutet (43)
Lunds universitet (21)
Göteborgs universitet (20)
Uppsala universitet (11)
Kungliga Tekniska Högskolan (6)
Umeå universitet (2)
visa fler...
Stockholms universitet (2)
Linköpings universitet (1)
RISE (1)
visa färre...
Språk
Engelska (84)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (48)
Naturvetenskap (4)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy